Dementia Discovery Fund

Cerevance is a developer of novel therapeutics intended to advance new medicines for serious neurological diseases.The company's therapeutics applies it's technology called NETSseq to reveal transcriptional and epigenetic differences between specific cell types in mature human brains, enabling healthcare providers to detect and tackle the early onset of various neurological diseases.

LoQus23 is a DDF-formed company focussing on targeting DNA damage repair pathways to treat Huntington’s disease and other triplet repeat diseases.

Transine Therapeutics

Rheostat’s mission is to invent novel treatments for neurodegenerative disease through modulation of mitophagy and autophagy. They believe that the degradation of toxic cellular components, whether they are damaged organelles or aggregated proteins, is a fundamental node of biology. Mutations that impair these clearance pathways cause multiple neurodegenerative diseases, many of which are associated with cognitive impairment. They aim to leverage our understanding of these critical pathways to discover and develop novel small molecules that will restore cellular balance and treat neurodegenerative and rare diseases.

LoQus23 is a DDF-formed company focussing on targeting DNA damage repair pathways to treat Huntington’s disease and other triplet repeat diseases.

Nitrome Biosciences, Inc. provides a platform to discover and identify drugs against newly identified class of enzymes. The company targets Parkinson’s disease and develops cures for various aging-dependent diseases, including neurodegenerative, Type II diabetes, heart, and cancer diseases. Nitrome Biosciences, Inc. was formerly known as Nitrome, Inc. The company was incorporated in 2012 and is headquartered in Jackson, Wyoming. It has sites in Jackson, Wyoming; and San Francisco, California.

Ribometrix is a platform therapeutics company that discovers small molecule drugs that target functional 3D RNA structures to treat human diseases. Our scientific offices are located in the newly renovated Biolabs Space in Durham, with offices in Chapel Hill and Boston.

Transine Therapeutics

Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a monoclonal microbial candidate, which is in Phase 1b placebo-controlled dose-escalating safety and tolerability clinical study for the treatment of psoriasis or atopic dermatitis. The company is also developing monoclonal microbial candidates, which are in pre-clinical development stage include EDP1815 for treating psoriatic arthritis, rheumatoid arthritis, and axial spondyloarthritis; EDP1867 for asthma; EDP2939 for inflammatory disease; and EDP1632 for neuro-inflammatory diseases. In addition, it is developing EDP1503, a monoclonal microbial candidate, which is in Phase 1/2 clinical study for the treatment of colorectal cancer, triple-negative breast cancer, and melanoma, as well as patients who have relapsed on prior PD-1/L1 inhibitor treatment. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Ribometrix is a platform therapeutics company that discovers small molecule drugs that target functional 3D RNA structures to treat human diseases. Our scientific offices are located in the newly renovated Biolabs Space in Durham, with offices in Chapel Hill and Boston.

Therini Bio is dedicated to the research and development of novel therapeutics for the treatment of neurological diseases. The company's approach is based on novel findings by the Akassoglou lab at Gladstone/UCSF that implicate fibrin as a key driver of neuroinflammation.

Based in Madison, Wis., Nordic is the largest Epic consulting practice in the world and the industry leader in providing electronic health record (EHR) consulting services to healthcare organizations using Epic software. Nordic is the only firm to be ranked No. 1 by KLAS in Epic Implementation Support and Staffing since the report’s inception in 2012. In the most recent Best in KLAS Report, Nordic was named the KLAS Category Leader for the “Other Implementation” category, which includes services and methodology in revenue cycle, integration, lab and reporting. Founded in 2010, Nordic has worked with more than 125 clients in 40 states, partnering with more than a third of Epic’s clients.

Alchemab Therapeutics is developing natural protective antibodies designed to keep people free of hard-to-treat diseases. They are building their transformative engine to identify novel drug targets and develop a broad pipeline of novel antibody therapeutics for hard-to-treat cancers, neurodegenerative conditions, and infectious diseases.

AstronauTx is a UCL spin-off, will develop medicines designed to reset the behaviour of astrocytes.

Nitrome Biosciences, Inc. provides a platform to discover and identify drugs against newly identified class of enzymes. The company targets Parkinson’s disease and develops cures for various aging-dependent diseases, including neurodegenerative, Type II diabetes, heart, and cancer diseases. Nitrome Biosciences, Inc. was formerly known as Nitrome, Inc. The company was incorporated in 2012 and is headquartered in Jackson, Wyoming. It has sites in Jackson, Wyoming; and San Francisco, California.

Cerevance is a developer of novel therapeutics intended to advance new medicines for serious neurological diseases.The company's therapeutics applies it's technology called NETSseq to reveal transcriptional and epigenetic differences between specific cell types in mature human brains, enabling healthcare providers to detect and tackle the early onset of various neurological diseases.

Mitoconix Bio Ltd develops a novel strategy to improve mitochondrial health as a disease modifying therapeutic for neurodegenerative diseases. The company was founded in 2016 and is based in Jerusalem, Israel.

Therini Bio is dedicated to the research and development of novel therapeutics for the treatment of neurological diseases. The company's approach is based on novel findings by the Akassoglou lab at Gladstone/UCSF that implicate fibrin as a key driver of neuroinflammation.

Cerevance is a developer of novel therapeutics intended to advance new medicines for serious neurological diseases.The company's therapeutics applies it's technology called NETSseq to reveal transcriptional and epigenetic differences between specific cell types in mature human brains, enabling healthcare providers to detect and tackle the early onset of various neurological diseases.

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in phase II clinical trial for the treatment of frontotemporal dementia disease; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer’s and Parkinson’s diseases. The company also offers AL002 and AL003, which are in phase 1b clinical trial for the treatment of Alzheimer’s disease. In addition, it has 10 programs under research and development stage. The company has a collaboration agreement with Adimab, LLC for the research and development of antibodies. Alector, Inc. was founded in 2013 and is headquartered in South San Francisco, California.

Cerevance is a developer of novel therapeutics intended to advance new medicines for serious neurological diseases.The company's therapeutics applies it's technology called NETSseq to reveal transcriptional and epigenetic differences between specific cell types in mature human brains, enabling healthcare providers to detect and tackle the early onset of various neurological diseases.

QurAlis Corporation discovers and develops therapeutics for the treatment of amyotrophic lateral sclerosis (ALS) and other neurological diseases. The company’s pipeline includes treatments for subtypes of ALS, such as a drug to restore a dysfunctional cellular waste clearance system that poisons neurons; a therapy to treat overactive neurons and prevents resulting cell death; and an approach to remove toxic proteins. The company was incorporated in 2016 and is based in Cambridge, Massachusetts. QurAlis Corporation operates as a subsidiary of Q-State Biosciences, Inc.

Autifony Therapeutics Limited, a biotechnology company, develops medicines to treat hearing disorders such as hearing loss and tinnitus. The company was incorporated in 2011 and is based in London, United Kingdom.

BrainWaveBank Limited, a brain health research company, develops data-centric solutions for tracking brain health that allow consumers to battle dementia. The company offers BrainWaveBank, a solution that allows individuals to measure and track their cognitive health on daily basis at home that helps to understand brain health and cognitive illness. Its platform uses a wearable headset to measures brain health with user’s responses while playing mobile games that challenge various cognitive skills with recordings of their brain activity. The company was founded in 2015 and is based in Belfast, United Kingdom.

Gen2 Neuroscience develops therapeutics for the treatment of dementia targeting abnormal forms of the essential cellular protein tau.

Tiaki Therapeutics is committed to developing microglia-targeted therapeutics for the treatment of dementias. Tiaki is at the forefront of harnessing microglial function. Using insights from academia, Tiaki is developing a platform to discover small molecule therapeutics which will restore microglial function in the aging brain. Tiaki is funded by the Dementia Discovery Fund, a venture capital fund which invests in projects and companies to discover and develop novel, effective, disease-modifying therapeutics for dementia.

Ribometrix is a platform therapeutics company that discovers small molecule drugs that target functional 3D RNA structures to treat human diseases. Our scientific offices are located in the newly renovated Biolabs Space in Durham, with offices in Chapel Hill and Boston.

Transine Therapeutics